Discontinued — last reported Q2 '25
AbbVie Epkinly — Collaboration revenues increased by 36.1% to $49.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 69.0%, from $29.00M to $49.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful commercialization or development milestones achieved through partnerships, while a decrease may suggest reduced partnership activity or the expiration of collaborative terms.
This metric represents the portion of total revenue generated from Epkinly that is derived from collaborative arrangemen...
Similar to 'collaboration revenue' or 'partnered product revenue' reported by other pharmaceutical companies engaged in co-development or co-promotion agreements.
abbv_segment_epkinly_collaboration_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.00M | $14.00M | $22.00M | $29.00M | $31.00M | $36.00M | $36.00M | $49.00M |
| QoQ Change | — | — | — | — | — | — | — | — | +0.0% | +57.1% | +31.8% | +6.9% | +16.1% | +0.0% | +36.1% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | +121.4% | +157.1% | +63.6% | +69.0% |